IMRX

Immuneering Corp

3.74

Oct 30 • 3:59 PM ET -0.28 (-6.84%)

3.69

Aftermarket • 7:30 PM ET -0.05 (-1.47%)

Healthcare Biotechnology USA Micro NASD

Oct 29, 6:45 PMImmuneering reports Q3 2026 results with non-GAAP EPS -0.37 (+3% YoY), revenue $0, misses EPS but beats revenue estimates

Peers: VSTM RVMD BBOT ERAS TNGX ELTX RCUS CRDF TOVX BLRX

| Held by: VTI IWM VXF IWN IBB VTWO IWC SBIO AVSC BUSM

Scroll to Statements

Index	RUT
Market Cap	242.54M
Enterprise Value	100.66M
Income	-66.50M
Sales	0.00M
Book/sh	2.60
Cash/sh	2.25
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	37
IPO	Jul 30, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.44
P/C	1.67
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	13.97
Current Ratio	13.97
Debt/Eq	0.02
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-1.03
EPS next Y	-1.55
EPS next Q	-0.40
EPS this Y	2.92%
EPS next Y	-25.38%
EPS next 5Y	-3.65%
EPS past 3/5Y	12.72% -13.77%
Sales past 3/5Y	- -
EPS Y/Y TTM	42.34%
Sales Y/Y TTM	-
EPS Q/Q	0.90%
Sales Q/Q	-
Earnings	Oct 29 AMC
EPS/Sales Surpr.	-21.31% -

Insider Own	14.02%
Insider Trans	0.09%
Inst Own	55.14%
Inst Trans	12.07%
ROA	-31.40%
ROE	-33.53%
ROIC	-38.72%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.72%
SMA50	-12.56%
SMA200	-22.12%
Trades

Shs Outstand	64.76M
Shs Float	55.68M
Short Float	29.32%
Short Ratio	23.32
Short Interest	16.32M
52W High	8.48 -55.84%
52W Low	3.38 10.80%
Volatility	6.73% 5.51%
ATR (14)	0.21
RSI (14)	43.27
Beta	0.47
Rel Volume	1.63
Avg Volume	699.93K
Volume	1,138,921

Perf Week	0.40%
Perf Month	-7.07%
Perf Quarter	-10.19%
Perf Half Y	-30.26%
Perf YTD	-43.09%
Perf Year	-41.58%
Perf 3Y	-37.16%
Perf 5Y	-86.18%
Perf 10Y	-
Recom	1.00
Target Price	17.00
Prev Close	4.02
Price	3.74
Change %	-6.84%

Consensus

Strong Buy

Avg. Price Target

$17.00

Implied Upside

+353.9%

Analysts11incl. previous ratings

Rating Distribution8 Buy · 2 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 06, 2026	Initiated	HH.C. Wainwright	Buy	$14	+273.8%
Jul 08, 2026	Initiated	CCantor Fitzgerald	Overweight	$17	+353.9%
Oct 31, 2025	Initiated	LLeerink Partners	Outperform	$15	+300.5%
Dec 13, 2024	Downgrade	MMorgan Stanley	Equal-Weight → Underweight
Mar 15, 2024	Reiterated	NNeedham	Buy	$20 → $15	+300.5%
Mar 15, 2024	Downgrade	TTD Cowen	Outperform → Market Perform
Mar 15, 2024	Downgrade	JJefferies	Buy → Hold	$16 → $3	-19.9%
Dec 01, 2023	Initiated	NNeedham	Buy	$20	+434.0%
Jun 26, 2023	Resumed	OOppenheimer	Outperform	$25	+567.6%
Apr 19, 2023	Upgrade	MMorgan Stanley	Underweight → Equal-Weight	$5 → $14	+273.8%
Apr 19, 2023	Upgrade	MMizuho	Neutral → Buy	$10 → $20	+434.0%
Mar 30, 2023	Initiated	MMizuho	Neutral	$10	+167.0%
Feb 03, 2023	Downgrade	MMorgan Stanley	Equal-Weight → Underweight	$12 → $5	+33.5%
Jul 08, 2022	Initiated	CChardan Capital Markets	Buy	$18	+380.6%
Apr 01, 2022	Initiated	OOppenheimer	Outperform	$25	+567.6%
Jan 07, 2022	Initiated	PPiper Sandler	Overweight	$41	+994.8%

Oct-29-26 04:05PM	Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) -6.84%
Oct-26-26 07:30AM	Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026 (GlobeNewswire)
Oct-02-26 09:00AM	Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Sep-28-26 07:30AM	Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer (GlobeNewswire)
Sep-24-26 07:30AM	Immuneering to Present at the ESMO Congress 2026 (GlobeNewswire)
07:30AM	Loading…
Sep-10-26 07:30AM	Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival (GlobeNewswire)
Sep-03-26 04:05PM	Immuneering to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-26 05:16PM	Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients (GlobeNewswire)
Aug-06-26 09:48AM	Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls (The Fly)
Aug-05-26 07:30AM	Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-21-26 04:05PM	Publication in Cancer Research Details Atebimetinib's Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition (GlobeNewswire)
Jul-17-26 04:05PM	Immuneering Corporation Announces Grants of Inducement Awards (GlobeNewswire) -7.54%
Jun-15-26 07:30AM	Immuneering Appoints Andrew Gengos as Chief Financial Officer (GlobeNewswire)
Jun-11-26 07:30AM	Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer (GlobeNewswire) +5.10%
Jun-01-26 03:58PM	IMRX Stock On Track For Worst Day In Nearly 5 Months Whats Driving The Selloff? (Stocktwits) -22.10%
07:30AM	Loading…
07:30AM	Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO (GlobeNewswire)
May-21-26 05:00PM	Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy (GlobeNewswire)
May-15-26 07:35AM	Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-21-26 04:05PM	Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting (GlobeNewswire) +6.13%
Apr-20-26 09:00AM	Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond (GlobeNewswire)
Apr-06-26 04:05PM	Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-26 04:35PM	Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival (GlobeNewswire)
Mar-09-26 11:15AM	X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention (24/7 Wall St.) +5.44%
Mar-06-26 07:45AM	Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire) +7.03%
Mar-02-26 04:05PM	Immuneering to Present at the Leerink Global Healthcare Conference (GlobeNewswire)
Feb-28-26 02:07AM	Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 (MarketBeat)
Feb-18-26 04:05PM	Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-08-26 09:28AM	Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower (Benzinga) -43.22%
05:17AM	Stock Market Today: S&P 500, Dow Jones Futures Decline - AZZ, Northrop Grumman, Immuneering In Focus (Benzinga)
Jan-07-26 07:03PM	Immuneering Highlights 64% 12-Month Survival in Phase 2A Pancreatic Cancer Study, Eyes Phase 3 (MarketBeat) +23.96%
04:00PM	Loading…
04:00PM	Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP (GlobeNewswire)
Dec-29-25 12:00PM	All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy (Zacks)
Dec-23-25 08:00AM	Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 (GlobeNewswire) +8.12%
Dec-17-25 04:05PM	Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA (GlobeNewswire)
Dec-16-25 08:00AM	Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire)
Dec-12-25 10:47AM	Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance (PR Newswire)
Nov-26-25 12:00PM	Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High? (Zacks)
Nov-25-25 08:00AM	Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-12-25 04:05PM	Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates (GlobeNewswire)
Nov-10-25 11:21AM	Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? (Zacks)
Nov-04-25 04:05PM	Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 (GlobeNewswire)
Oct-31-25 09:33AM	Apple upgraded, Comcast downgraded: Wall Street's top analyst calls (The Fly) +7.18%
Sep-30-25 11:42AM	Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) (Insider Monkey)
Sep-26-25 04:01PM	Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 (GlobeNewswire) -16.46%
Sep-25-25 12:08AM	Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi (GlobeNewswire) -13.33%
Sep-24-25 04:05PM	Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi (GlobeNewswire) +7.45%
04:01PM	Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP (GlobeNewswire)
Sep-16-25 07:00AM	Immuneering Appoints Dr. Thomas Schall as Chairman of the Board (GlobeNewswire) +5.73%
Sep-10-25 07:00AM	Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 (GlobeNewswire) +15.46%
Aug-26-25 04:05PM	Immuneering Announces Closing of $25 Million Private Placement (GlobeNewswire) -12.33%
11:17AM	Immuneering Stock Rises 21.7% on Supply Agreement With LLY (Zacks)
Aug-25-25 08:00AM	Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib (GlobeNewswire) +21.68%
Aug-21-25 08:00AM	Immuneering Announces $25 Million Private Placement (GlobeNewswire) +34.99%
Aug-13-25 04:05PM	Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.59%
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire)
Jul-09-25 08:00AM	Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib (GlobeNewswire) +11.25%
Jul-08-25 04:00AM	The MEK effect on cancer a slow and steady approach to drug resistance (Pharma Voice)
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -7.58%
Jun-17-25 06:00AM	Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients (GlobeNewswire) -23.21%
Jun-16-25 08:00AM	Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 (GlobeNewswire) +24.74%
May-29-25 08:00AM	Immuneering to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -5.83%
May-05-25 04:05PM	Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-02-25 08:00AM	Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-25 04:30PM	Immuneering Corporation Announces Grant of Inducement Award (GlobeNewswire) +9.09%
Mar-20-25 04:05PM	Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
07:12AM	Immuneering names Igor Matushansky as chief medical officer (SeekingAlpha)
07:00AM	Immuneering Names Dr. Igor Matushansky as Chief Medical Officer (GlobeNewswire)
Feb-06-25 07:00AM	Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo (cemiplimab) (GlobeNewswire)
Feb-03-25 04:05PM	Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-13-25 08:00AM	Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer (GlobeNewswire)
Jan-07-25 09:28AM	Why Is Immuneering Stock Trading Higher On Tuesday? (Benzinga)
07:00AM	Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms (GlobeNewswire)
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire) +10.00%
Dec-19-24 08:00AM	Immuneering Launches Pancreatic Cancer Advisory Board (GlobeNewswire) +13.58%
Dec-17-24 08:00AM	Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025 (GlobeNewswire)
Dec-13-24 02:10PM	Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? (Benzinga) -17.01%
Dec-12-24 08:00AM	Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma (GlobeNewswire) -7.94%
Nov-27-24 08:00AM	Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference (GlobeNewswire)
Nov-13-24 04:05PM	Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.56% +13.45%
Oct-15-24 08:00AM	Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer (GlobeNewswire) +15.50%
Sep-13-24 08:14AM	Why Is Nanocap Immuneering Stock Trading Higher On Friday? (Benzinga) +41.26%
Sep-12-24 04:05PM	Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients (GlobeNewswire) +10.85%
Aug-29-24 08:00AM	Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-06-24 04:05PM	Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.06%
Jul-31-24 04:05PM	Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer (GlobeNewswire) +19.47%
May-29-24 04:05PM	Immuneering to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire)
May-07-24 10:55PM	IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024 (InvestorPlace) -5.45%
04:05PM	Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-06-24 04:30PM	Immuneering Recognizes Melanoma Awareness Month (GlobeNewswire)
Apr-09-24 12:00PM	IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models (GlobeNewswire)
Apr-03-24 04:05PM	Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-24 08:00AM	Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire)
Mar-18-24 11:02AM	Immuneering (IMRX) Plummets 71% in One Week: Here's Why (Zacks) +34.03%
Mar-14-24 07:00AM	Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors (GlobeNewswire) -50.68%
Mar-12-24 08:00AM	Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors (GlobeNewswire)
Mar-11-24 08:00AM	Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors (GlobeNewswire) -9.53%
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 05:00PM	Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zeskind Benjamin J.	PRESIDENT AND CEO	Jun 23 '26	Buy	4.56	2,400	10,948	2,315,252	Jun 24 04:11 PM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Jun 15 '26	Buy	4.15	6,035	25,045	382,531	Jun 16 04:15 PM
Brakewood Harold Eugene	Chief Business Officer	Jan 16 '26	Buy	4.76	5,250	24,990	11,050	Jan 21 09:09 AM
Schall Thomas J.	Director	Jan 15 '26	Buy	4.67	21,645	101,041	74,530	Jan 20 09:17 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Jan 15 '26	Buy	4.57	2,298	10,502	376,496	Jan 16 04:07 PM
Neufeld Leah R	CHIEF PEOPLE OFFICER	Jan 13 '26	Buy	4.15	2,626	10,906	25,970	Jan 15 08:06 AM
Feinberg Peter	Director	Jan 12 '26	Buy	4.35	20,000	86,904	135,441	Jan 14 08:10 AM

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Ph.D.Dr. Benjamin J. Zeskind M.B.A.

M.S.Mr. Robert J. Carpenter M.B.A.

Chief Scientific OfficerDr. Brett M. Hall Ph.D.

Chief Legal Officer & SecretaryMr. Michael D. Bookman J.D.

CFO & TreasurerMr. Andrew W. Gengos

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMRX

Immuneering Corp

Upgrade your Finviz experience